Neuraminidase deficiency in the mouse  by Potier, Michel et al.
Volume 108, number 2 FEBS LETTERS December 1979 
NEURAh,HNIDASE DEFICIENCY IN THE MOUSE 
Michel POTIER, Denise LU SHUN YAN and James E. WOMACK* 
Section de G&re’tique Medicale, Centre de Recherche P~d~~.que, genital ~~r~te~utine, University de Montr.+al, Mon~~aI, 
Quebec, H3T ICY.5 Canada and *Department of Veterinary Pathology, Institute of comparative Medicine, 
Texas A and M University, College Station, TX 77843, USA 
Received 9October 1979 
1. Introduction 
The liver of mouse strain SM/J expresses unique 
electrophoretic patterns of the lysosomal enzymes 
acid phosphatase (EC 3.1.3.2) [I], cw-mannosidase 
(EC 3.2.1.24) [2] and arylsulfatase B (EC 3.1.6.1) 
[3]. For each of these enzymes, the more electro- 
negative forms are enhanced whereas less negatively 
charged forms are depleted or absent. Genes involved 
in post-transcriptional processing of lysosomal enzymes 
have been implicated and each were mapped to 
appro~mately the same region of chromosome 17 
[2-4]. The SM/J electrophoretic patterns can be 
converted to that of control mouse strains by pre- 
treatment with bacterial neuraminidase (EC 3.2 .l .18). 
These data have led us to consider the possibility 
that SMfJ carries a unique allele for a single gene, 
perhaps involved in the production of neuraminidase, 
and that other lysosomal enzymes are processed 
differentially as dictated by alleles at this locus, Here 
we report profound neuraminidase deficiency in the 
liver of SM/J mice. 
2. Materials and methods 
2.1 .Materials 
N-Acetylneuraminic acid (type IV) and bovine 
serum albumin (Cohn fraction V) were purchased 
from Sigma Chemical, St Louis, MO. The sodium 
(4-methylumbelliferyl-cr-D-N-acetylneuraminate) was 
synthesized in our laboratory [5]. Inbred C57BL/6J 
and SM/J mice were obtained from the Jackson 
Laboratory, Bar Harbor, ME. 
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2 2. Animals and tissues 
Mice (5-10 weeks old) were killed by cervical 
dislocation. Liver, kidney, heart, lung and brain were 
dissected and immediately placed on ice. Homogenates 
(0.1 g tissue/ml water) were prepared at 0°C in a 
Potter-Elvejhem homogenizer (3 min treatment) 
fitted with a Teflon pestle. To prevent rapid inactiva- 
tion of neuraminidase the homogenate was immediately 
made 12 mM in CaC&. With CaClz, the homogenate 
can be stored for months at -6O’C without loss of 
neuram~idase activity. Freshly prepared or stored 
homogenates were used for neuraminidase assay. 
2.3. Neuraminidase assay 
Neuraminidase activity was assayed at 25’C 
according to [5] with 0.1 mM sodium (4-methyl- 
.umbelliferyl~-D-~-ace~~eur~ate) as substrate, 
except that a 0.2 M acetate buffer (pH 4.4) was used 
in the incubation medium and that the reaction was 
stopped after 20 min by addition of 1 ml absolute 
ethanol. Protein was then centrifuged at 2000 X g 
for 10 min, the supernatant (I ml) was collected and 
mixed with 0.1 ml 1 M NaOH just before reading 
fluorescence with an Aminco-Bowman model 768-H 
spectrofluorometer (excitation, 365 nm; emission, 
450 nm). 
Total sialic acid content of C57BL/6J and SM/J 
livers was determined after hydrolysis in 0.05 M 
H2SOe at 80°C for 1 h. Free sialic acid was measured 
according to [6] after purification by passage through a 
Dowex 1 X 8 column (200-400 mesh, acetate form, 
0.6 X 4 cm). The column was washed with distilled 
water and sialic acid was then eluted with 4 ml 0.84 M 
formic acid. The sialic acid containing fraction was 
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lyophilized and the residue was taken up in 0.2 ml 
water. 
2.4. K, upp and K, determinations 
Apparent Michae~s-Menten constant, Km app, 
was determined under standard assay conditions with 
sodium (4-methylumbelIiferyl~-D-N-acetyIneuramin- 
ate) except that substrate concentration was varied 
between 0.08 and 0.4 mM. A Lineweaver-Burk plot 
was used for graphical determination of Km app 171. 
Apparent inl~bition constal~t, Ki, for N-acetyl- 
neuraminic acid was determined using 2-10 mM 
inhibitor concentrations, and 0.05,O.lO and 0.20 mM 
substrate concentrations, by the method in [8]. 
2.5. Protein concentration 
This was determ~ed by the method in [9] with 
bovine serum albumin as standard. Before assay, 
protein was dissolved in 0.1 M NaOH. 
3. Results 
Although neuraminidase is a relatively labile 
enzyme, minimal loss of activity occurred during 
homogeneization of mouse liver. Neuraminidase 
activity was assayed at 30 s intervals during the 
homogenization procedure and maxinlum activity 
was obtained after the first 30 s of treatment. How- 
ever, a satisfactory homogenate was obtained only 
after a 3 min treatment. At least 80% of the initial 
enzyme activity was still present after 3 min. It is 
critical that the homogenates be made 12 mM in 
C&I2 immediately after homogenization because 
neuraminidase is lost rapidly (half-life 1 .1-l .3 h) 
in absence of CaClz. The optimal concentration 
was found to be 12 mM CaC12 in which condi- 
tions half-life of neuraminidase was 14- 15 h. The 
neuram~idase activity was stable during the assay 
since tinearity with incubation time (< 30 min) and 
amount of homogenate protein (G 1.2 mg/ml) was 
obtained. 
Neuraminidase activity was significantly lower 
than control (strain C57BL/6J) in liver of SM/J mice 
and (~57BL~6JxSM/J)F, hybrids, 17% and 48%, 
respectively (P < 0.01, table 1). Enzyme activity was 
also reduced to 35% of control in SM/J lung@ < 0.05) 
but for other organs, the lower activity found in SM/J 
mice was not statistically significant (P > 0.05). 
Mixtures of equal volumes of control and SMfJ liver 
homogenatesgave intermediate neuraminidase activity 
ruling out the presence of inhibitors or activators. 
Liver homogenates from C57BL/6J and SM/J did not 
differ significantly in their sialic acid content, 
23.8 rf 4.9 pmol/g protein (mean + SD) for control 
liver and 20.7 i 5.1 for SM/J liver (P > 0.05, n = 9). 
Two neuraminidase components, A and B, are 
present in control mouse liver which can be dis- 
tinguished on the basis of their stability at 0°C in 
absence of CaClz (fig.1). The more labile component 
(A) has a half-life of 1 .I -1.3 h (calculated between 
0 and 1 h incubation at 0°C) and represent 82-85% 
of total liver neuraminidase activity. For comparison 
purposes, a preparation of the B component was 
obtained essentially free of A activity by incubation 
of a fresh homogenate for 24 h at 0°C without CaCIZ. 
Table 1 
Neuraminidase activity in mouse organ@ 
Organ 
C57BL/6J 
Mouse Strain 
CS7BL/6JXSM/J (F,) 
._. 
SM/J 
Liver 3.37 + 0.80 (lO)b 1.62 * 0.91 (4)C 0.56 r 0.13 (S)C 
Kidney 7.89 2 1.93 (4) 7.45 f 4.39 (2) 6.00 f 1.44 (5) 
Heart 0.37 + 0.18 (5) 0.42 f 0.17 (3) 0.35 * 0.15 (4) 
Lung 0.68 c 0.27 (4) 0.56 i 0.10 (3) 0.24 f 0.11 (4)d 
Brain 0.61 f 0.06 (3) - 0.53 * 0.13 (3) 
a Neuraminidase activity expressed in gmoI4-meth~~lumbelliferone released. 
It-’ . g protein-’ 
b Mean f SD. Figures in parentheses refer to the number of animals used. Signif- 
icantly different from the C57BL/6J strain at ‘P < 0.01 and d P < 0.05 
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Fig.1. Effect of preincubation time at 0°C on neuraminidase 
activity in two control C57BL/6J (o,*) and two SM/J mice 
(o,m). The crude homogenate in water was preincubated for 
different intervals of time, without substrate, and then 
assayed at 25°C under standard assay conditions. 
The half-life of the B component was similar to that 
of residual neuraminidase activity in SM/J liver (half- 
life, 4 l-44 h). Both B component and SM/J enzyme 
also showed identical pH optima (3.8), Km app with 
sodium (4-methylumbelliferyl~-D-N-acetylneuramin- 
ate) as substrate (55-63 PM), and Ki with the com- 
petitive inhibitor N-acetylneuraminic acid (1.6 mM). 
The pH optima for total neuraminidase of control 
liverwas4.4,theKm app,28-30pM and Ki,0.8 mM. 
4. Discussion 
We report neuraminidase deficiency in liver of 
mouse strain SM/J using sodium (4-methylumbelli- 
feryla-D-N-acetylneuraminate) as substrate (table 1). 
The other SM/J organs are also affected but to a 
lesser extent than liver. The neuraminidase deficiency 
in SM/J strain is unique as indicated by a survey of 
2 1 different mouse strains [lo]. 
Two neuraminidase components (A,B) were iden- 
tified in C57BL/6J liver on the basis of their different 
stabilities at 0°C. Available evidence suggests that 
SM/J liver is deficient in the more labile component 
A. Residual neuraminidase activity in SM/J liver (17%) 
approximately corresponded to the liver B content of 
strain C57BL/6J (1 S- 18%) and both SM/J enzyme 
and B component showed similar half-life at 0°C 
(41-44 h) and kinetic properties. It is not known 
whether a structural gene of neuraminidase or a gene 
for neuraminidase activity or transformation of B into 
A form is involved in SM/J. The half-reduced neuraminid- 
ase activity in liver of Fr hybrids (table 1) is con- 
sistent with a single structural gene hypothesis but 
does not eliminate other alternatives. A paper is in 
preparation where genetic aspects of neuraminidase 
deficiency will be fully discussed [lo]. 
SM/J liver expresses unique electrophoretic 
patterns of acid phosphatase [11, a-mannosidase [2] 
and arylsulfatase B [3] where electronegative, 
sialylated forms of these enzymes are enhanced as 
compared to controls. However, there is apparently 
no gross alteration of sialic acid metabolism in SM/J 
liver since total sialic acid content was slightly, but 
not significantly, lower than controls. The observa- 
tion that the normal electrophoretic patterns can be 
restored by in vitro treatment with bacterial 
neuraminidase suggests the possibility that the 
neuraminidase deficiency is responsible for abnormal 
electrophoretic patterns of lysosomal enzymes in 
SM/J liver. Needleman et al. [ 1 l] suggested that 
neuraminidase plays a role in the post-transcriptional 
modification of lysosomal enzymes by progressive 
cleavage of terminal sialic acid residues in the lyso- 
somes, or during transfer of lysosomal enzymes to the 
lysosomes. 
It is not clear at present how the biochemical 
abnormalities in SM/J mice are related to recently 
described neuraminidase deficiency syndromes in 
man: mucolipidosis type I [ 12-141, and the cherry- 
red spots myoclonus syndrome with [ 151 and with-, 
out dementia [ 16 ,171. However, the SM/J mouse can 
be useful as a model for enzyme therapy of these 
diseases, and for understanding the role of neuraminid- 
ase in the processing post-transcriptional modifi- 
cations of lysosomal enzymes. 
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